Related Experiment Video
Updated: Mar 22, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Targeting cancer stem cells with p53 modulators
Zhan Zhang1, Ling Liu1,2, Roberto Gomez-Casal3,4
1Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Cancer stem cells (CSC) typically over-express aldehyde dehydrogenase (ALDH). Thus, ALDHbright tumor cells represent targets for developing novel cancer prevention/treatment interventions. Loss of p53 function is a common genetic event during cancer development wherein small molecular weight compounds (SMWC) that restore p53 function and reverse tumor growth have been identified. Here, we focused on two widely studied p53 SMWC, CP-31398 and PRIMA-1, to target ALDHbright CSC in human breast, endometrial and pancreas carcinoma cell lines expressing mutant or wild type (WT) p53. CP-31398 and PRIMA-1 significantly reduced CSC content and sphere formation by these cell lines in vitro. In addition, these agents were more effective in vitro against CSC compared to cisplatin and gemcitabine, two often-used chemotherapeutic agents. We also tested a combinatorial treatment in methylcholantrene (MCA)-treated mice consisting of p53 SMWC and p53-based vaccines. Yet using survival end-point analysis, no increased efficacy in the presence of either p53 SMWC alone or with vaccine compared to vaccine alone was observed. These results may be due, in part, to the presence of immune cells, such as activated lymphocytes expressing WT p53 at levels comparable to some tumor cells, wherein further increase of p53 expression by p53 SMWC may alter survival of these immune cells and negatively impact an effective immune response. Continuous exposure of mice to MCA may have also interfered with the action of these p53 SMWC, including potential direct interaction with MCA. Nonetheless, the effect of p53 SMWC on CSC and cancer treatment remains of great interest.
Insights
Small molecular weight compounds (SMWC) targeting p53 show promise in reducing cancer stem cells (CSC) and sphere formation in vitro. However, in vivo studies combining SMWC with vaccines did not improve survival outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cancer stem cells (CSCs) often over-express aldehyde dehydrogenase (ALDH), making ALDHbright cells a therapeutic target.
- Loss of p53 function is a frequent event in cancer, and small molecular weight compounds (SMWC) can restore p53 function.
- CP-31398 and PRIMA-1 are studied p53 SMWC with potential to impact CSCs.
Purpose of the Study:
- To investigate the efficacy of p53 SMWC (CP-31398 and PRIMA-1) against ALDHbright CSCs in various human carcinoma cell lines.
- To compare the in vitro effectiveness of these p53 SMWC against CSCs with conventional chemotherapeutic agents.
- To evaluate the in vivo efficacy of a combination therapy involving p53 SMWC and p53-based vaccines in a mouse model.
Main Methods:
- Utilized human breast, endometrial, and pancreas carcinoma cell lines with mutant or wild type (WT) p53.
- Assessed CSC content and sphere formation in vitro following treatment with CP-31398 and PRIMA-1.
- Compared treatment outcomes with cisplatin and gemcitabine.
- Conducted in vivo studies using methylcholantrene (MCA)-treated mice with a combination of p53 SMWC and p53-based vaccines, analyzing survival endpoints.
Main Results:
- CP-31398 and PRIMA-1 significantly reduced CSC content and sphere formation in vitro.
- These p53 SMWC demonstrated superior in vitro efficacy against CSCs compared to cisplatin and gemcitabine.
- Combination therapy with p53 SMWC and vaccines in mice did not yield improved survival compared to vaccine alone.
Conclusions:
- p53 SMWC effectively target ALDHbright CSCs and inhibit their growth in vitro, offering a potential new avenue for cancer treatment.
- The lack of enhanced efficacy in vivo may be attributed to complex interactions with immune cells expressing WT p53 or interference from the continuous MCA exposure.
- Further research into p53 SMWC for cancer treatment is warranted, considering their significant impact on CSCs.
More Related Videos
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
07:03Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...